Literature DB >> 27622035

Missense mutations in the perforin (PRF1) gene as a cause of hereditary cancer predisposition.

Mohammed S Chaudhry1, Kimberly C Gilmour2, Imran G House3, Mark Layton1, Nicki Panoskaltsis1, Mamta Sohal4, Joseph A Trapani3, Ilia Voskoboinik3.   

Abstract

Perforin, a pore-forming toxin released from secretory granules of NK cells and CTLs, is essential for their cytotoxic activity against infected or cancerous target cells. Bi-allelic loss-of-function mutations in the perforin gene are invariably associated with a fatal immunoregulatory disorder, familial haemophagocytic lymphohistiocytosis type 2 (FHL2), in infants. More recently, it has also been recognized that partial loss of perforin function can cause disease in later life, including delayed onset FHL2 and haematological malignancies. Herein, we report a family in which a wide range of systemic inflammatory and neoplastic manifestations have occurred across three generations. We found that disease was linked to two missense perforin gene mutations (encoding A91V, R410W) that cause protein misfolding and partial loss of activity. These cases link the partial loss of perforin function with some solid tumors that are known to be controlled by the immune system, as well as haematological cancers. Our findings also demonstrate that perforin gene mutations can contribute to hereditary cancer predisposition.

Entities:  

Keywords:  Hereditary cancer; perforin; protein misfolding

Year:  2016        PMID: 27622035      PMCID: PMC5006901          DOI: 10.1080/2162402X.2016.1179415

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  25 in total

Review 1.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

2.  Perforin A91V polymorphism and putative susceptibility to hematological malignancies.

Authors:  S Muralitharan; Y Wali; A V Pathare
Journal:  Leukemia       Date:  2006-10-12       Impact factor: 11.528

3.  Perforin activity and immune homeostasis: the common A91V polymorphism in perforin results in both presynaptic and postsynaptic defects in function.

Authors:  Ilia Voskoboinik; Vivien R Sutton; Annette Ciccone; Colin M House; Jenny Chia; Phillip K Darcy; Hideo Yagita; Joseph A Trapani
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

4.  Perforin forms transient pores on the target cell plasma membrane to facilitate rapid access of granzymes during killer cell attack.

Authors:  Jamie A Lopez; Olivia Susanto; Misty R Jenkins; Natalya Lukoyanova; Vivien R Sutton; Ruby H P Law; Angus Johnston; Catherina H Bird; Phillip I Bird; James C Whisstock; Joseph A Trapani; Helen R Saibil; Ilia Voskoboinik
Journal:  Blood       Date:  2013-02-01       Impact factor: 22.113

5.  Perforin is a major contributor to NK cell control of tumor metastasis.

Authors:  M J Smyth; K Y Thia; E Cretney; J M Kelly; M B Snook; C A Forbes; A A Scalzo
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

6.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

7.  A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin.

Authors:  Christina Trambas; Federico Gallo; Daniela Pende; Stefania Marcenaro; Lorenzo Moretta; Carmela De Fusco; Alessandra Santoro; Luigi Notarangelo; Maurizio Arico; Gillian M Griffiths
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

8.  Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma.

Authors:  Sonia Cannella; Alessandra Santoro; Giuseppa Bruno; Marta Pillon; Lara Mussolin; Giovanna Mangili; Angelo Rosolen; Maurizio Aricò
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

9.  Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer.

Authors:  Jenny Chia; Kim Pin Yeo; James C Whisstock; Michelle A Dunstone; Joseph A Trapani; Ilia Voskoboinik
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-01       Impact factor: 11.205

Review 10.  Perforinopathy: a spectrum of human immune disease caused by defective perforin delivery or function.

Authors:  Ilia Voskoboinik; Joseph A Trapani
Journal:  Front Immunol       Date:  2013-12-12       Impact factor: 7.561

View more
  3 in total

1.  Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors.

Authors:  Kate H Gartlan; Jagdish K Jaiswal; Matthew R Bull; Hedieh Akhlaghi; Vivien R Sutton; Kylie A Alexander; Karshing Chang; Geoffrey R Hill; Christian K Miller; Patrick D O'Connor; Jiney Jose; Joseph A Trapani; Susan A Charman; Julie A Spicer; Stephen M F Jamieson
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-31

Review 2.  Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework.

Authors:  Oskar A Haas
Journal:  Front Immunol       Date:  2019-02-12       Impact factor: 7.561

3.  Gene therapy of prostate cancer using liposomes containing perforin expression vector driven by the promoter of prostate-specific antigen gene.

Authors:  Kosuke Mizutani; Kyojiro Kawakami; Yasunori Fujita; Taku Kato; Manabu Takai; Daiki Kato; Koji Iinuma; Takuya Koie; Masafumi Ito
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.